CoChat

Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis

Open access
Wang, Jing, Chen, Yalei, Xu, Weihao, Lu, Nianfang, Cao, Jian, Yu, Shengyuan · 2019 · PLOS ONE

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Previous studies have demonstrated that intensive blood pressure (BP) lowering treatment reduces the risk of all-cause mortality and provides greater vascular protection for patients with hypertension. Whether intensive BP lowering treatment is associated with such benefits in patients with type 2 diabetes mellitus remain unknown. We aimed to clarify these benefits by method of meta-analysis. METHODS: The PubMed, EMBASE, Science Citation Index and Cochrane Library databases were searched to identify randomized controlled trials (RCT) that fulfilled study inclusion criteria. Two investigators independently extracted and summarized the relevant data of the included trials. Random-effects model was applied to calculate the estimates of all effect measures. RESULTS: We included 16 RCTs and our meta-analysis showed that intensive BP lowering treatment vs less intensive BP lowering treatment resulted in significant reductions in the all-cause mortality risk [relative risk (RR), 0.82; 95% CI, 0.70-0.96], major CV events (RR, 0.82; 95% CI, 0.73-0.92, MI (RR, 0.86; 95% CI, 0.77-0.96), stroke (RR, 0.72; 95% CI, 0.60-0.88, CV death (RR, 0.73; 95% CI, 0.58-0.92) and albuminuria progression (RR, 0.91 95% CI, 0.84-0.98). However, intensive BP lowering treatment had no clear effect on non-CV death (RR, 0.97; 95% CI, 0.79-1.20), heart failure (HF) (RR, 0.88; 95% CI, 0.71-1.08) or end-stage kidney disease (ESKD) (RR, 1.00; 95% CI, 0.75-1.33). Subgroup analysis showed that the reduction in all cause-mortality was consistent across most patient groups, and intensive BP lowering treatment had a clear benefit even in patients with systolic blood pressure lower than 140 mm Hg. However, the benefit differed in patients with different CV risk (≥10%: RR, 0.77, 95%CI, 0.64-0.91; <10%: RR, 1.04, 95%CI, 0.84-1.29; Phetero = 0.028). CONCLUSIONS: Our data indicate that intensive BP lowering treatment provides greater benefits than less intensive treatment among patients with type 2 diabetes mellitus. Further studies are required to more clearly evaluate the benefits and harms of BP targets below those currently recommended with intensive BP lowering treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0215362

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Flowchart of trial identification for meta-analysis.
Fig 1 Flowchart of trial identification for meta-analysis.CC BY · PubMed Central
Fig 2 (A) Forest plot showing the effects of intensive versus less intensive blood pressure lowering treatment on all-cause mortality; (B) Plot of sensitivity analysis by excluding one study each time and the pooling estimate for the rest of the studies; (C) Funnel plot of publication bias test.
Fig 2 (A) Forest plot showing the effects of intensive versus less intensive blood pressure lowering treatment on all-cause mortality; (B) Plot of sensitivity analysis by excluding one study each time and the pooling estimate for the rest of the studies; (C) Funnel plot of publication bias test.CC BY · PubMed Central
Fig 3 Effects of intensive blood pressure lowering on risk of cardiovascular outcomes (A) Major cardiovascular events; (B) Myocardial infarction; (C) Stroke.
Fig 3 Effects of intensive blood pressure lowering on risk of cardiovascular outcomes (A) Major cardiovascular events; (B) Myocardial infarction; (C) Stroke.CC BY · PubMed Central
Fig 4 Effects of intensive blood pressure lowering on risk of cardiovascular outcomes (A) Cardiovascular death; (B) Non-cardiovascular death; (C) Heart failure.
Fig 4 Effects of intensive blood pressure lowering on risk of cardiovascular outcomes (A) Cardiovascular death; (B) Non-cardiovascular death; (C) Heart failure.CC BY · PubMed Central
Fig 5 Effects of intensive blood pressure lowering on risk of renal outcomes (A) End stage kidney disease; (B) Albuminuria progression.
Fig 5 Effects of intensive blood pressure lowering on risk of renal outcomes (A) End stage kidney disease; (B) Albuminuria progression.CC BY · PubMed Central
Fig 6 Effect of intensive blood pressure lowering on the risk of all-cause mortality in subgroups of trials.
Fig 6 Effect of intensive blood pressure lowering on the risk of all-cause mortality in subgroups of trials.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

Metadata

Authors
Wang, J., Chen, Y., Xu, W., Lu, N., Cao, J., & Yu, S.
Affiliations
  • Nankai University (CN)
  • Chinese PLA General Hospital (CN)
Corresponding author
  • Cao, Jian
  • Yu, Shengyuan
Venue
PLOS ONE
Published
2019-04-12
Volume
14
Issue
4
Pages
e0215362
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2940192148
Cited by
45
References
55
Citations by year
2026: 1 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 8 · 2021: 2 · 2020: 12 · 2019: 1
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Special Project of Healthcare Scientific Research of Military (16BJZ15)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
intensive blood pressure lowering, type 2 diabetes, all-cause mortality, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, albuminuria, heart failure, end-stage renal disease, systolic blood pressure, cardiovascular risk stratification, antihypertensive therapy, renal protection, subgroup analysis
MeSH terms
Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Kidney Failure, Chronic, Male, Risk Factors, Randomized Controlled Trials as Topic, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.